VivoSeq
Oncology

Advanced Lymphoma

32

Pipeline Programs↗

2

Active Trials↗

12

Companies Involved↗

Advanced Lymphoma is a moderately active landscape with 32 programs across 12 companies. The most active players are Roche, AstraZeneca, Boehringer Ingelheim.

Intelligence

Pipeline Metrics

Competitive Density

53/100

Pipeline Velocity

0/100

Mech. Concentration

10/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Roche logo

Roche

4 programs

Phase 2AstraZeneca logo

AstraZeneca

3 programs

Phase 2Boehringer Ingelheim logo

Boehringer Ingelheim

2 programs

Phase 2Pfizer logo

Pfizer

2 programs

Phase 2Bayer logo

Bayer

2 programs

Phase 2Novartis logo

Novartis

2 programs

Phase 2

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 232

AZD1775

AstraZeneca

Afatinib

Boehringer Ingelheim

Afatinib Dimaleate

Boehringer Ingelheim

Binimetinib

Pfizer

Capivasertib

AstraZeneca

Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

79%

Small molecule

23 of 29 classified programs — the dominant modality here.

21%ALL OTHERSMonoclonal antibody414%Antibody–drug conjugate13%Protein / enzyme13%

Small molecule leads; the ring shows all 29 classified programs, each share of the total. Modality classified for 91% of 32 pipeline programs.

Analysis

Trial Status

2

clinical trials

Active, not recruiting2 · 100%

Clinical Trials

Trial Activity

Molecular Analysis for Therapy Choice (MATCH)
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT02465060·6,452 enrolled
MATCH Treatment Subprotocol Z1B: Phase II Study of Palbociclib (PD-0332991) in Patients With Tumors With CCND1, 2, 3 Amplification
Active, not recruiting·National Cancer Institute (NCI)·Phase 2·NCT04439201·40 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)